Vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and RAF kinases (VEGFR/PDGFR/RAF)

The VEGFR/PDGFR/RAF kinase profile represents a critical multi-target axis in oncology, combining receptor tyrosine kinases (RTKs) and intracellular serine/threonine kinases. Vascular endothelial growth factor receptors (VEGFR-1, -2, -3) and platelet-derived growth factor receptors (PDGFR-alpha, -beta) are primary mediators of neo-angiogenesis and stromal support, facilitating the formation of new blood vessels and the maintenance of the tumor microenvironment. RAF kinases (including RAF-1 and B-RAF) are essential components of the MAPK/ERK signaling pathway, which drives tumor cell proliferation and survival. By simultaneously inhibiting these targets, multi-kinase inhibitors exert a dual effect: they starve the tumor of oxygen and nutrients by disrupting its blood supply while directly blocking the intracellular signals that promote cancer cell growth. This multi-pronged approach is particularly effective in highly vascularized tumors and those driven by dysregulated kinase signaling, such as renal and hepatocellular carcinomas.

Other names

VEGFR-PDGFR-RAF axisMulti-kinase target profileAngiogenic and oncogenic kinase targetsSorafenib/Regorafenib target profile

Multi-kinase inhibition involving the blockade of ATP-binding sites on receptor tyrosine kinases (VEGFR, PDGFR) to inhibit angiogenesis and intracellular serine/threonine kinases (RAF) to inhibit the MAPK/ERK proliferation pathway.